Propanc Biopharma Advances PRP into Phase 1b Study with $7.5M in Funding

  • Propanc Biopharma raised $7.5M in the 2025-26 fiscal year, including a $4M public offering and $3M from Series C convertible preferred stock.
  • The company plans to commence a Phase 1b first-in-human (FIH) study of PRP in Q1 2027, targeting advanced solid tumors including pancreatic, ovarian, and refractory prostate cancers.
  • Preclinical data shows PRP achieved >90% tumor growth inhibition in PDAC models and extended median overall survival by more than 2.5-fold.
  • Propanc signed an MOU with Avance Clinical to support the Phase 1b study and secured a CDMO for GMP manufacture of PRP.

Propanc Biopharma's advancement of PRP into a Phase 1b study marks a significant milestone in its quest to develop novel treatments for recurrent and metastatic cancer. The company's strategic partnerships and securing of funding highlight its commitment to accelerating clinical development. However, the biotech faces intense competition in the oncology space, where breakthroughs in targeted therapies and immunotherapy are reshaping the treatment landscape.

Clinical Execution
Whether Propanc can successfully initiate and complete the Phase 1b study as planned, given the complexity of the trial design and the need for rapid ethics approval.
Funding Sustainability
The pace at which Propanc can secure additional funding to support later-phase development, given the $100M private placement agreement and the need for continued investment.
Competitive Positioning
How Propanc's PRP differentiates itself in the crowded oncology space, particularly in light of advancements in KRAS inhibitors and other targeted therapies.